INITIATOR PHARMA: 1 QUARTER REPORT 2020
Clinical progress and expanded pipelineBusiness highlights in Q1 2020 · On March 15[th] we reported the final data from the company’s Phase 2a study with IPED2015, demonstrating statistically significant and clinically relevant results on key efficacy endpoints in patients with severe ED after a single administration of IPED2015. As previously reported, the Phase 2a study was completed satisfactorily with no observations of critical adverse events. · On March 31st we announced that we have filed a Phase 2a Clinical Trial Application (CTA) to MHRA, UK, for our candidate drug IP2018.